A new analysis of dozens of animal studies evaluating the effects of the cholesterol-lowering statin class of drugs on atherosclerosis found larger positive effects in studies not sponsored by the pharmaceutical industry as compared to those that were industry sponsored.
Health policy expert Lisa Bero, PhD, is hailed in the latest issue of The Lancet for tackling hot-button subjects such as financial biases in drug research.
Research studies can be designed to influence the results, comments Lisa Bero, PhD, UCSF School of Pharmacy faculty member and expert on industry sponsorship of research and conflict of interest.
